Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort study by Chen, Hsin-Hua et al.
CLINICAL SCIENCE
Gender differences in ankylosing
spondylitis-associated cumulative healthcare
utilization: a population-based cohort study
Hsin-Hua Chen,
I,II,V Tzeng-Ji Chen,
I,II Yi-Ming Chen,
I,II Chiu Ying-Ming,
IV Der-Yuan Chen
I,II,V
ITaichung Veterans General Hospital - Division of Allergy, Immunology and Rheumatology, Taiwan.
IINational Yang-Ming University - School of Medicine,
Taipei, Taiwan.
IIIChanghua Christian Hospital - Division of Allergy, Immunology and Rheumatology.
IVChunghua, Taiwan, Chung-Shan Medical
University - School of Medicine Taichung, Taiwan.
VChung-Shan Medical University - School of Medicine, Taichung, Taiwan.
BACKGROUND: Ankylosing spondylitis (AS) is one of the most common rheumatic diseases with gender differences
in prevalence and clinical presentation. This study aimed to examine whether such gender differences are correlated
with cumulative healthcare utilization in Taiwan.
METHODS: The National Health Insurance Research Database supplied claim records of one million individuals from
1996 to 2007. Selected cases included patients aged $16 years. Certified rheumatologists diagnosed the patients in
three or more visits and gave prescriptions for AS. Multivariate adjusted logistic regression analyses were used to
calculate the influence of gender on cumulative healthcare utilization associated with AS.
RESULTS: The study included 228 women and 636 men. After adjustment for potential confounding factors, men
had more cumulative outpatient visits associated with AS (odds ratio, 1.59; 95% confidence interval, 1.13 -2.23;
p=0.008). Men also exhibited a trend for higher frequency of AS-related hospitalization (p=0.054).
CONCLUSION: Men are more likely to have high cumulative AS-associated healthcare utilization than women.
Further investigation of the causal factors is warranted.
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INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease characterized by pain and stiffness of the
back and peripheral joints, with extra-articular manifesta-
tions.
1 It often develops in late adolescence but is usually
diagnosed in young adults.
1 It is one of the most common
rheumatic diseases with gender differences in prevalence
and clinical presentation.
2 Although there is male predomi-
nance, the ratio of men to women has declined from 9-10:1
in earlier studies
3-4 to 2-3:1 in recent ones.
5-8
Previous studies also show that women have a longer
delay in diagnosis, more pain in the cervical spine and
peripheral joints, less thoracic and lumbar spinal radio-
graphic severity, lower Bath Ankylosing Spondylitis
Radiology Index scores, and more functional limitations at
the same level of radiographic damage.
2,7 However,
whether there are gender differences in cumulative health-
care utilization is unknown.
The purpose of this study was to examine the influence of
gender on healthcare utilization associated with AS, based
on the Taiwanese National Health Insurance Research
Database (NHIRD) from 1996 to 2007.
PATIENTS AND METHODS
Data source
The source of data was the NHIRD, covering in-patient
and ambulatory care claims in the period 1996-2007. In
Taiwan, the compulsory National Health Insurance
Program was implemented in March 1995 and covered
more than 95% of the population.
9 The Bureau of National
Health Insurance (NHI) was the sole buyer of health
services and regulated payments for medical care. Its
computerized database was a good source for a popula-
tion-based study.
This study used a representative database extracted
randomly from the entire NHIRD dataset in 2005. The
database had 1 000 000 persons, or approximately 5% of
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251Taiwan’s population. Because the NHIRD consisted of de-
identified secondary data released to the public for research
purposes, this study was exempt from full review by the
Internal Review Board. Self-treatment with over-the-counter
(OTC) medications or alternative health services were not
included in the database.
Although blood tests and radiographic data were not
available in the database, the Bureau of NHI audited the
accuracy of diagnoses by routinely sampling patient charts
randomly to cross-check claims from all hospitals. Any
hospital found to have discrepancies, malpractice, or over-
charging faced heavy penalties. The audit of the Bureau of
NHI promoted the accuracy of coding.
10
Patients
This was a retrospective cohort study. Only those who
had claims data in 2006 and 2007 were selected to exclude
those who might be dead or lost to follow-up after 2005
(n=893 859). The AS cases were defined as those with the
diagnostic code of AS (code 720.0 in the International
Classification of Diseases, Ninth Revision [ICD-9]) listed for
an out-patient visit or hospitalization (i.e. provider-diag-
nosed AS). Those with three or more AS-associated out-
patient visits, with prescription of AS-related drugs (i.e.
non-steroid anti-inflammatory drugs [NSAIDs], methotrex-
ate, sulfasalazine, steroids) were selected (n=1608). To
minimize the possibility of misdiagnosis, only those with at
least three consensus AS diagnoses by certified rheumatol-
ogists were initially included (n=976). Those aged ,16
years in 1996 (n=112) were also excluded. In the end, 228
women and 636 men with AS were included.
Variables of interest
Gender was the independent variable of interest.
Outcome variables included cumulative out-patient visits,
frequency of ophthalmic out-patient visit for uveitis,
frequency of emergencies, AS-associated in-patient and
rehabilitation visits, and frequencies of prescribed AS-
related drugs. Healthcare utilization data was dichoto-
mized, i.e. high vs. low, according to the 50
th percentile
because these were not normally distributed.
Potential confounders included age, duration of follow-
up (period between the date of first AS-associated visit and
end of 2007), insured amount, and Charlson co-morbidity
index (CCI). Insured amount was calculated from the
patients’ average monthly income and thus, also served as
an economic index. Insured amount were transformed to
ordinal variables according to the 25
th,5 0
th and 75
th
percentile. CCI, adapted by D’Hoore,
11 was calculated using
diagnostic dose (ICD-9) listed for any out-patient and in-
patient visits between the date of the first and the last AS-
related visit. CCI was grouped into four ordinal categories:
0, 1, 2, and $3.
Statistical analysis
To examine the unadjusted male-female comparisons, t
tests were used for normally distributed continuous vari-
ables, Mann-Whitney U tests for continuous variables that
were not normally distributed, and x
2 tests for categorical
variables. Correlations between ordinal variables were
studied using the Kendall Tau rank correlation coefficient,
while correlations between dichotomous variables were
studied using the Phi correlation efficient.
Multivariate adjusted logistic regression was used to
examine the influence of gender on outcome variables. A
two-tailed p,0.05 was considered statistically significant.
All statistical calculations were performed using the
Statistical Package for the Social Sciences (SPSS) for
Windows Version 13.0 (SPSS, Inc., Chicago, Illinois).
RESULTS
The study cohort included 228 women and 636 men with
AS. Their economic-demographic data and co-morbidity
were compared in Table 1. Men showed an earlier age onset
of healthcare utilization. Further analysis for ordinal
variables showed a weak but positive correlation between
age and Charlson co-morbidity index (Kendall’s tau rank
correlation coefficient = 0.189, p,0.001).
The cumulative AS-associated healthcare utilization
between men and women were compared in Table 2. Men
had higher risks of having higher cumulative healthcare
visits associated with AS and showed a trend for higher
frequency of hospitalization (p=0.076). Frequencies of AS-
related drug use between men and women were not
different. There was a significant positive correlation
between use of sulfasalazine and use of methotrexate (Phi
correlation coefficient = 0.167, p,0.001).
After adjustment for gender, age, follow-up duration,
insured amount, and CCI, men had increased risk of higher
cumulative out-patient visits compared to women (odds
ratio [OR] 1.59, 95% confidence interval [CI]: 1.13-2.23,
p=0.008) (Table 3). Men also showed a trend for higher
frequency of hospitalization (p=0.054). Other significant
predictors of higher healthcare utilization included longer
follow-up duration and higher CCI.
Table 1 - Comparison of economic, demographic and
co-morbidity between men and women with ankylosing
spondylitis patients*.
Women (n=228) Men (n=636) p value
Age (yrs) 32 (25-41) 30 (23-39) 0.034
Age group (yrs) 0.204
16-30 (%) 43.0 50.5
31-45 (%) 42.5 39.3
46-60 (%) 13.2 8.8
61-75 (%) 1.3 1.3
.75 (%) 0.0 0.2
Age at utilization onset**
(yrs),
38 (30-46) 35 (28-44) 0.001
Insured amount
group(NT$)
,0.001
, 12800 (%) 32.0 21.5 0.002
12800-20000 (%) 29.8 26.6 0.343
20000-31000 (%) 21.5 22.8 0.712
.31000 (%) 16.7 29.1 ,0.001
Charlson comorbidity index
group
,0.001
0 (%) 45.2 60.1 ,0.001
1 (%) 24.1 12.7 ,0.001
2 (%) 11.8 8.6 0.187
§3 (%) 18.9 18.6 0.921
*Values are median (inter-quartile range).
**Age at utilization onset was defined as the age of initial out-patient or
in-patient visit. P values were determined by chi-square tests.
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The main question addressed by this study is whether or
not there is gender difference in healthcare utilization
associated with ankylosing spondylitis. By current knowl-
edge, this is the first study to demonstrate that men are
more likely to have higher cumulative AS-associated out-
patient visits compared to women. Singh et al., using a
population based administrative database, report that
gender does not influence healthcare utilization in AS
patients.
12 However, in contrast to the current study, theirs
investigated both AS and non-AS related healthcare utiliza-
tion and for only one year.
12 Moreover, their study has been
limited in examining the gender factor because of male
predominance in the veteran population.
12
There are several possible explanations to the findings
here. First, men may have worse disease severity that drives
higher healthcare utilization. Worse severity in men has
been reported by Lee et al.
7 However, different from the
current cohort, their cohort is composed of AS patients
with .20 years duration and older age.
7 Second, the longer
delay in diagnosis in women previously reported
2 may be a
cause of later age of utilization onset found in this study and
lead to an underestimation of healthcare utilization.
Another possibility is the existence of gender difference in
the general preference for healthcare utilization. However,
the finding that men have lower healthcare utilization than
women in a recent study from Taiwan provides supportive
evidence to exclude this possibility.
13
The present study reveals a male-to-female ratio of 2.79,
consistent with recent reports.
5-8, 14 Unlike the PSOAS
cohort,
7 women in this cohort do not have higher
frequencies of sulfasalazine, methotrexate, and intra-articu-
lar steroid use. Furthermore, frequencies of sulfasalazine
and steroid use in this cohort are higher than those in the
PSOAS cohort. These differences may be due to a recall bias
in the PSOAS cohort or ethnic differences.
This study has three advantages. First, use of an
administrative database avoids the problem of under-
reporting at higher numbers of visit.
15 Previous studies
show that healthcare utilization in AS patients assessed in
administrative databases
11,16-17 is higher than that assessed
by patient report.
8,14,18-19 Second, a long observation period
offers the opportunity to capture the real impact of AS.
Third, this study has adjusted for confounding factors,
including age, gender, follow-up duration, economic status,
and Charlson co-morbidity index (CCI). The CCI, originally
developed to predict mortality from medical records,
20 has
been adapted for administrative databases that use the
International Classification of Diseases, Ninth Revision
(ICD-9).
11 CCI also reportedly influences healthcare utiliza-
tion in osteoarthritis, a chronic rheumatic disease.
21 This
study assumes that CCI may also influence healthcare
utilization in AS and the data proves this. Although other
possible confounding factors, including educational level,
marital status, employment status, race, and current smok-
ing status are unknown, none are significant predictors in
the Singh’s study.
12 Furthermore, over 98% of Taiwan’s
residents are of Chinese Han ethnicity, so the homogenous
population is unlikely to be confounded by race. However,
it also limits the generalization of the study result to other
ethnicities.
This study has several limitations. First, although restric-
tive inclusion criteria have been used, bias due to miscoding
and misclassification can still happen. Second, although this
study uses a 12-year database, underestimation of health-
care utilization in patients with earlier or later disease onset
cannot be discounted. Third, the NHIRD lacks the informa-
tion for self-treatment with OTC medications, which may be
Table 2 - Comparison of cumulative healthcare utilization
associated with ankylosing spondylitis between men and
women (1996-2007)*.
Women (n=228) Men (n=636) p value
Follow-up duration (yrs) 5.8 (3.1-8.0) 7.1 (4.7-8.7) ,0.001
Number of outpatient
visits
15.0 (9.0-31.8) 22.0 (12.0-47.0) ,0.001
§ 21 outpatient
visits (%)
39.0 53.9 ,0.001
§1 hospitalization (%) 7.0 10.5 0.076
§1 emergent visit (%) 6.6 5.5 0.620
§1 REHA visit (%) 16.7 20.9 0.176
§1 OPH visit for
uveitis (%)
18.4 17.3 0.686
NSAID use (%) 100 99.8 1.000
Methotrexate use (%) 21.5 16.7 0.108
Sulfasalazine use (%) 81.6 86.9 0.062
Oral steroid use (%) 86.8 83.6 0.287
Intra-articular steroid
use (%)
2.6 2.8 1.000
*Values are median (inter-quartile range)
Abbreviations: REHA, rehabilitation; OPH, ophthalmic; NSAID, non-
steroidal anti-inflammatory drugs
Table 3 - Significant predictors of utilization associated with ankylosing spondylitis, by multivariate analyses*.
Model characteristics Outpatient visits (high) Hospitalization (yes)
Hosmer-Lemeshow test 11.326 (p=0.184) 5.362 (p=0.068)
Nagelkerke R
2 0.173 0.250
-2 log likelihood 1077.399 439.114
Significant predictors OR (95% CI) P-value OR (95% CI) P-value
Male gender 1.59 (1.13-2.23) 0.008 1.83 (0.99-3.41) 0.054
Follow-up duration 1.26 (1.19-1.34) ,0.001 1.24 (1.10-1.39) ,0.001
CCI ,0.001 ,0.001
1 1.64 (1.08-2.48) 0.020 11.34 (5.11-25.13) ,0.001
2 1.42 (0.86-2.34) 0.173 6.86 (2.71-17.38) ,0.001
§3 2.43 (1.60-3.67) ,0.001 15.67 (7.43-33.07) ,0.001
*Multivariable regression models adjusted for the following variables: gender, age, follow-up duration, Charlson co-morbidity index, and insured
amount.
Abbreviation: CCI, Charlson co-morbidity index
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253a confounding factor. However, a recent study from Taiwan
does not reveal gender in preference for OTC medication
use.
22 Lastly, other possible confounding factors like the
duration of leaving, retirement status, and disease duration
are unavailable in the NHIRD. However, if a Taiwanese
resident migrates to other countries, the Bureau of NHI will
abrogate his/her insurance.
This study excludes those without claims data in 2006 and
2007, which ensured that the enrolled patients did not have
long-term leaving. As for short-term leaving, because the
Bureau of NHI allows patients’ families to visit doctors and
take medicines for the patients, the influence of short-term
leaving on the number of out-patient visits may be reduced.
Because the insured amount is determined by average
monthly income, the adjustment for insured amount in this
study may also comprise adjustments for the status of
retirement.
The true disease duration of AS is difficult to obtain via
claims data because the duration between age at symptom
onset and age at diagnosis usually lasts for several years and
varies widely.
1 Ward’s study also shows that cumulative
five-year total costs of AS, which may be related to
cumulative out-patient and in-patient visits, are not influ-
enced by disease duration.
23
In conclusion, this study demonstrates that men are more
likely to have higher cumulated AS-associated out-patients
visits compared to women. Further studies are required to
examine whether higher AS-related cumulative healthcare
utilization in men is caused by worse disease severity and/
or shorter delay in diagnosis.
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